SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " ab science " 16 found 🔀 AI-powered Shuffle
Pittcon: Lab Science Conference and Expo Explained
Pittcon explained: who runs it, what the technical program, short courses and exposition offer labs, and how proceeds fund science outreach. Next: April 2027.
10 years of Jackson Lab science shows the lifesaving power of genome-matched cancer treatment
These treatments have already changed the lives of Mainers battling the disease. Thankfully, more work lies ahead.
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.
PRESS RELEASE AB SCIENCE WILL HOLD A WEB CONFERENCE ON WEDNESDAY, OCTOBER 14, FROM 6:00 P.M. TO 7:30 P.M. Paris, October 12, 2026, 6:00 p.m. AB...
AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.
PRESS RELEASE AB SCIENCE WILL HOLD A WEB CONFERENCE ON WEDNESDAY, OCTOBER 14, FROM 6:00 P.M. TO 7:30 P.M. Paris, October 12, 2026, 6:00 p.m. AB Science SA (Euronext - FR0010557264 - AB) will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m. During this web conference, AB Science will address the following topics: Status update three months after the implementation of the new governance structureReview of the September 2026 Sponsor inspectionAB Science’s new outloo
AB Science’s “Calendar Update” Is a GCP Inspection Disclosure in Disguise
AB Science buried a five-inspector "for cause" GCP inspection inside a financial calendar update. Masitinib's ALS trial and three terminated studies deserve a…
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION ...
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION Confirmation of the relevance of having, among the first decisions of the new management, given priority to the development of a new quality management system Expected resumption of the AB8939 phase 1 (acute myeloid leukemia) in the first quarter of 2027, followed by the masitinib phase 3 (amyotrophic lateral sclerosis) in the last quarter of 2027, subj
Pittcon 2027: What America’s Biggest Lab Science Show Means For You
For over 75 years, Pittcon has been at the cutting edge of industry-defining changes, and next year it returns home for the first time in six decades.
AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 14.2 MILLION PRIVATE PLACEMENT, PRIMARILY SUSBCRIBED BY LONG TERM INVESTOR AB...
AB Science ends three studies in multiple sclerosis, other immune conditions
The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.
AB Science cuts three trials in pipeline reset
French biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leukaemia.
AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML
PRESS RELEASE AB SCIENCE REPORTS COMPLETION OF THE STEP 3 OF PHASE 1, EVALUATING THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA THE COMBINATION OF AB8939 WITH VENETOCLAX GENERATED A 67% OVERALL RESPONSE RATE (ORR) AND A 100% DISEASE CONTROL RATE (DCR), WITH NO DOSE-LIMITING TOXICITIES (DLT) OBSERVED, IN A POOR-PROGNOSIS POPULATION WITH ADVERSE GENETICS TREATED IN THE SECOND - TO FOURTH-LINE RELAPSED OR REFRACTORY SETTING Paris, June 2
2026 guest artist and composer transform Fermilab science into art
Fermi Forward Discovery Group’s annual guest artist and composer program fosters creative collaborations that help translate Fermilab’s complex scientific research into accessible, engaging experiences. In 2026, visual artist Eleftheria Lialios and composer Isaac Smith will bring their distinct perspectives to transform particle physics data into immersive visual and auditory works for the public.
Anonymous $50 million donation helps cover the next 50 years of tuition for medical lab science students at University of Washington
“I’m really shocked,” said Jasmine Wertz, eyes filling with tears. “Overwhelmed. Extremely grateful.”
UW: Anonymous $50M gift will cover tuition for med lab science students
The anonymous gift is estimated to bring $50 million over the next 50 years to UW's Department of Laboratory Medicine and Pathology.